Clinical trial
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are…
NCT00053157 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00053157 |
|---|---|
| Title | Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia |
| Official title | Use Of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) To Mobilize Donor Peripheral Blood Stem Cells Along With GM-CSF Administration Post Allogeneic Transplant - A Pilot Study |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms |
| Intervention type | Biological |
| Interventions | sargramostim |
| Enrollment | 10 |
| Start date | Jun 1, 2002 |
| Primary completion | Aug 1, 2004 |
| First posted | Jan 28, 2003 |
| Last update posted | Oct 5, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: